Baker BROS. Advisors LP Has $719,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Baker BROS. Advisors LP lessened its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 96.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,055 shares of the company’s stock after selling 1,993,345 shares during the period. Baker BROS. Advisors LP owned 2.60% of Aligos Therapeutics worth $719,000 at the end of the most recent reporting period.

Separately, Armistice Capital LLC raised its stake in Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Price Performance

Shares of ALGS opened at $25.51 on Monday. The firm has a 50 day simple moving average of $11.83 and a two-hundred day simple moving average of $12.61. Aligos Therapeutics, Inc. has a one year low of $6.76 and a one year high of $30.00. The company has a market cap of $91.53 million, a P/E ratio of -1.92 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. During the same quarter in the previous year, the business posted ($10.25) EPS. On average, analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).